Page 88 - CL Armchair Case

Shkreli – Thiola

Retrophin acquired the rights to sell Thiola, which is used to

treat cystinuria.

Sufferers of cystinrula may take the drug for life, starting in

early childhood, in an effort to manage the rare and

incurable disease that afflicts about 20,000 patients in the

United States and which causes sufferers' bodies to

constantly create kidney stones, causing excruciating pain,

severe organ damage and in some cases, death.

Thiola was approved to treat cystinuria by the US Food and

Drug Administration (FDA) in 1988 and was acquired by

Retrophin in May 2014.

In September 2014 Retrophin increased the price of Thiola

from $1.50 (£1) per pill to more than $30 (£20) for the same

product - an increase of almost 2,000 per cent.

Shares of Retrophin Inc jumped as much as 31 per cent

following the deal allowing it to market Thiola.